Medical history (history of illness) represents an important component in the diagnosis of acute renal failure (ANV). Family history
Social history
Current anamnesis/systemic anamnesis (somatic and psychological complaints).
- What complaints have you noticed?
- How long have these changes existed? Have you been injured?
- Do you have urinary urgency?
- How often do you need to urinate each day? When did you last urinate?
- Do you pass only small amounts of urine when you do so?
- Has the urine changed in color, consistency and quantity?
- Do you have any other complaints such as abdominal pain, fatigue, performance slump?
- Are you drinking enough? How much have you drunk today?
Vegetative anamnesis incl. nutritional anamnesis
- Has your appetite changed?
- Have you noticed any unwanted change in weight?
- Have you noticed any changes in digestion?
- Do you suffer from sleep disturbances?
- Do you smoke? If yes, how many cigarettes, cigars or pipes per day?
- Do you drink alcohol? If yes, what drink(s) and how many glasses per day?
- Do you use drugs? If yes, what drugs and how often per day or per week?
Self history incl. medication history.
- Pre-existing conditions
- Operations
- Allergies
Medication history
- ACE inhibitors and AT1- receptor antagonists (acute: decrease in glomerular filtration rate (GFR) associated with creatinine increase:ACE inhibitors as well as AT1 receptor antagonists abolish vasoconstriction in the vas efferens, and a decrease in GFR and increase in serum creatinine result. Up to 0.1 to 0.3 mg/dl, this is usually tolerable.However, in the presence of hemodynamically relevant renal artery stenosis (not uncommon in patients with atherosclerosis/arteriosclerosis), GFR becomes markedly angiotensin II-dependent, and administration of an ACE inhibitor or AT1 receptor antagonist may result in acute renal failure)!
- Angiotensin receptor neprilysin antagonists (ARNI) – dual drug combination: sacubitril/valsartan.
- Allopurinol
- Atypical antipsychotics (olanzapine, quetiapine, risperidone) – elderly patients have approximately 70% increased risk of hospitalization for acute renal failure (ANV) during the first three months of treatment with atypical antipsychotics
- Antiphlogistic and antipyretic analgesics (non-steroidal anti-inflammatory drugs (NSAID), non-steroidal anti-inflammatory drugs) or non-steroidal anti-inflammatory drugs (NSAID* ) Caution: the combination of a diuretic, an RAS blocker, and an NSAID is associated with a significant risk of acute kidney injury:
- Acetylsalicylic acid (ASA).
- Diclofenac
- Ibuprofen/naproxen
- Indometacin
- Metamizole (novaminsulfone) is a pyrazolone derivative and analgesic from the group of non-acidic non-opioid analgesics (highest analgesic and antipyretic activity. Side effects: Circulatory fluctuations, hypersensitivity reactions, and very rarely agranulocytosis.
- Paracetamol / acetaminophen
- Phenacetin (phenacetin nephritis)
- Selective COX-2 inhibitors such as rofecoxib, celecoxib (side effects: decreased sodium and water excretion, blood pressure increase and peripheral edema. This is usually accompanied by hyperkalemia!).
- Antibiotics
- Aminoglycoside antibiotics (aminoglycosides) – amikacin, gentamycin (gentamicin), netilmicin, paromomycin, streptomycin, tobramycin, vancomycin.
- Ampicillin (group of β-lactam antibiotics).
- Cephalosporins (cefuroxime, cefotiam).
- Amoxicillin
- Carbenicillin
- Ethambutol (tuberculostat)
- Fenoprofen
- Glycopeptide antibiotics (telavancin, vancomycin) – esp. piperacillin reduces vancomycin clearance.
- Gyrase inhibitors (extremely rare: acute interstitial nephritis after ciprofloaxin, ofloxacin and norfloxacin).
- Methicillin (penicillinase-resistant penicillin).
- Oxacillin
- Rifampicin (bactericidal antibiotic from the group of ansamycins).
- Sulfonamides such as sulfadiazine, cotrimoxazole (fixed combination of: trimethoprim + sulfamethoxazole).
- Tetracyclines (doxycycline)
- Antidiabetics
- SGLT2 inhibitors (canagliflozin and dapagliflozin); in predisposed patients (eg.B. Chronic kidney disease, dehydration, low blood pressure).
- Antifungals
- Polyenes (amphotericin B, liposomal amphotericin B, natamycin).
- Chloral hydrate
- Colchicine
- Diuretics
- Thiazide diuretics (hydrochlorothiazide (HCT), benzthiazide, clopamide, chlortalidone (CTDN), chlorothiazide, hydroflumethiazide, indapamide, methyclothiazide, metolazone, polythiazide and trichloromethiazide, xipamide) + elderly patients: Decrease in GFR of more than 25%.
- The combination of a diuretic, an RAS blocker, and an NSAID is associated with a significant risk of acute kidney injury.
- D-Penicillamine
- Gold – sodium aurothiomalate, auranofin
- Hydroxyethyl starch (HES)
- Immunosuppressants (ciclosporin (cyclosporin A)) – esp. ciprofloxacin plus ciclosporin A.
- Interferon
- Colloidal solution with hydroxyl starch
- Contrast media – Of particular importance here are magnetic resonance imaging (MRI) contrast media containing gadolinium, which can lead to nephrogenic systemic fibrosis (NSF). Particularly affected by NSF are patients with a glomerular filtration rate (GFR) of less than 30 ml/min. [CKD stage 4]; iodine-containing radiographic contrast agents; [require prophylactic irrigation in renal insufficiency]EMA (European Medicines Agency): categorization of GBCAs (gadolinium-based contrast agents) in terms of NSF (nephrogenic systemic fibrosis) risk, based on thermodynamic and kinetic properties:High risk:
- Gadoversetamide, gadodiamide (linear/non-ionic chelates) gadopentetate dimeglum (linear/ionic chelate).
Medium risk:
- Gadofosveset, gadoxetic acid disodium, gadobenate dimeglumine (linear/ionic chelates).
Low risk
- Gadoterate meglumine, gadoteridol, gadobutrol (macrocyclic chelates).
- Lithium
- Oncological therapy
- Immunotherapy – checkpoint inhibitors (monoclonal antibodies), bevacizumab (VEGF antibody), trastuzumab (HER2 antibody) – nivolumab (PD-1 antibody).
- Targeted therapies – “Targeted therapies”, everolimus (mTOR inhibitor), imatinib (tyrosine kinase inhibitor), vemurafenib (serine/threonine kinase inhibitor).
- Cytostatic drugs – carboplatin, cisplatin, cyclophosphamide, gemcitabine, iphosphamide (ifosfamide), melphalan, methotrexate (MTX), mitomycin C, platinum (cisplatin).
- Proton pump inhibitors (proton pump inhibitors, PPI; acid blockers).
- “Atherosclerosis Risk in Communities” (ARIC): 10-year PPI use: rate of chronic renal failure in patients on PPI 11.8%, without 8.5%; rate of renal damage: 64%; two pills a day resulted in significantly more frequent damage: 62%
- Geisinger Health System: observation period 6.2 years; rate of chronic renal failure disease: 17%; rate of renal damage: 31%; two pills a day resulted in significantly more frequent damage: 28%
- Rast blockers: the combination of a diuretic, an RAS blocker, and an NSAID is associated with a significant risk of acute kidney injury.
- X-ray contrast agent
- Statins (rhabdomyolysis)
- Tacrolism (macrolide derived from the gram-positive bacterium Streptomyces tsukubaensis. Tacrolimus is used as a drug in the group of immunomodulators or calcineurin inhibitors).
- Antivirals
- Nucleoside analogues (aciclovir, brivudine, cidofovir, famciclovir, ganciclovir, valaciclovir).
- Other (foscarnet)
Environmental history (including intoxications).
- Aliphatic hydrocarbons (2,2,4-trimethylpentane, decalin, unleaded gasoline, mitomycin C).
- Ethanol (ethanol; alcohol)
- Ethylene glycol (ethylene glycol)
- Halogenated hydrocarbons (HFC; trichloroethene, tetrachloroethene, hexachlorobutadiene, chloroform).
- Herbicides (paraquat, diquat, chlorinated phenoxyacetic acids).
- Cocaine
- Melamine
- Metals (cadmium, chromium, lead, lithium, nickel, mercury, uranium).
- Mycotoxins (ochratoxin A, citrinin, aflatoxin B1).
- Salicylate